Barclays’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-8,200
| Closed | -$697K | – | 5288 |
|
|
2020
Q3 | $697K | Sell |
8,200
-900
| -10% | -$45.5K | ﹤0.01% | 2974 |
|
|
2020
Q2 | $323K | Sell |
9,100
-39,600
| -81% | -$1.16M | ﹤0.01% | 3685 |
|
|
2020
Q1 | $656K | Sell |
48,700
-115,500
| -70% | -$1.94M | ﹤0.01% | 3359 |
|
|
2019
Q4 | $3.47M | Sell |
164,200
-5,500
| -3% | -$97K | ﹤0.01% | 2406 |
|
|
2019
Q3 | $2.25M | Sell |
169,700
-77,500
| -31% | -$1.14M | ﹤0.01% | 2714 |
|
|
2019
Q2 | $3.43M | Sell |
247,200
-77,200
| -24% | -$1.16M | ﹤0.01% | 2280 |
|
|
2019
Q1 | $6.23M | Buy |
324,400
+105,000
| +48% | +$1.69M | ﹤0.01% | 1506 |
|
|
2018
Q4 | $3.13M | Buy |
219,400
+118,600
| +118% | +$2.35M | ﹤0.01% | 1970 |
|
|
2018
Q3 | $2.1M | Sell |
100,800
-74,100
| -42% | -$1.76M | ﹤0.01% | 2816 |
|
|
2018
Q2 | $4.14M | Sell |
174,900
-223,700
| -56% | -$4.5M | ﹤0.01% | 1881 |
|
|
2018
Q1 | $5.82M | Buy |
398,600
+142,300
| +56% | +$2.33M | ﹤0.01% | 1534 |
|
|
2017
Q4 | $4.14M | Buy |
256,300
+12,400
| +5% | +$146K | ﹤0.01% | 1814 |
|
|
2017
Q3 | $3.41M | Sell |
243,900
-54,600
| -18% | -$544K | ﹤0.01% | 1837 |
|
|
2017
Q2 | $2.64M | Buy |
298,500
+144,900
| +94% | +$1.02M | ﹤0.01% | 2014 |
|
|
2017
Q1 | $994K | Sell |
153,600
-10,700
| -7% | -$54.2K | ﹤0.01% | 2744 |
|
|
2016
Q4 | $603K | Buy |
164,300
+103,400
| +170% | +$306K | ﹤0.01% | 3202 |
|
|
2016
Q3 | $198K | Buy |
60,900
+4,500
| +8% | +$12.6K | ﹤0.01% | 3979 |
|
|
2016
Q2 | $131K | Buy |
56,400
+4,300
| +8% | +$14.4K | ﹤0.01% | 4219 |
|
|
2016
Q1 | $104K | Buy |
52,100
+5,600
| +12% | +$12.6K | ﹤0.01% | 4326 |
|
|
2015
Q4 | $139K | Buy |
46,500
+5,000
| +12% | +$14K | ﹤0.01% | 4186 |
|
|
2015
Q3 | $41K | Sell |
41,500
-127,300
| -75% | -$325K | ﹤0.01% | 5128 |
|
|
2015
Q2 | $675K | Buy |
168,800
+84,600
| +100% | +$346K | ﹤0.01% | 3222 |
|
|
2015
Q1 | $253K | Buy |
84,200
+32,500
| +63% | +$141K | ﹤0.01% | 4160 |
|
|
2014
Q4 | $207K | Buy |
51,700
+8,500
| +20% | +$33.6K | ﹤0.01% | 4608 |
|
|
2014
Q3 | $130K | Sell |
43,200
-7,100
| -14% | -$24K | ﹤0.01% | 5121 |
|
|
2014
Q2 | $151K | Buy |
50,300
+15,800
| +46% | +$58K | ﹤0.01% | 5102 |
|
|
2014
Q1 | $138K | Sell |
34,500
-94,100
| -73% | -$467K | ﹤0.01% | 5149 |
|
|
2013
Q4 | $514K | Buy |
128,600
+11,400
| +10% | +$50.8K | ﹤0.01% | 4066 |
|
|
2013
Q3 | $703K | Buy |
117,200
+20,100
| +21% | +$116K | ﹤0.01% | 3729 |
|
|
2013
Q2 | $528K | Buy |
+97,100
| New | +$319K | ﹤0.01% | 4143 |
|
Barclays's IMMU Position: Q4 2020 in Review
Barclays sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 535,506 shares — an estimated $45.5M sold.
Barclays first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $45.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Barclays reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Barclays sold 535,506 Immunomedics Inc shares in Q4 2020, an estimated $45.5M.
- Barclays first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- Barclays's Immunomedics Inc position peaked at $45.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.